ARTICLE | Finance
Second wind
Why investors are backing another attempt at inhaled cyclosporine A from Breath
March 10, 2017 6:58 PM UTC
Gimv and Sofinnova Partners are backing Breath Therapeutics Holding B.V. with one of the largest European series A rounds in the past 10 years because they believe the company has solved the issues that prevented inhaled cyclosporine A from getting approved to treat lung transplant patients in the mid-2000s.
On March 8, Breath raised €43.5 million ($46.2 million) in a series A round co-led by Gimv and Sofinnova Partners, with Gilde Healthcare also participating. ...